eFFECTOR Therapeutics (EFTR) AI Stock Analysis

• Market Cap: $941.00
• Dividend Yield: N/A
• Average Volume (3M): 38.30K
• Price to Earnings (P/E): ―
• Beta (1Y): -56.82
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): -13.31
• Shares Outstanding: 4,704,409
• 10 Day Avg. Volume: 22,048
• 30 Day Avg. Volume: 38,305
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 25 Underperform
• Price Target: ―

eFFECTOR Therapeutics' overall score is primarily impacted by severe financial distress, with declining revenue, negative equity, and reliance on external financing. The absence of technical indicators and negative valuation metrics further hinder the stock's attractiveness. Lack of earnings call insights limits understanding of future prospects. Strategic changes are critical for improvement.

eFFECTOR Therapeutics Business Overview & Revenue Model

Company Description

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.

How the Company Makes Money

eFFECTOR Therapeutics makes money primarily through the development and potential commercialization of its proprietary drug candidates. The company generates revenue through strategic collaborations and partnerships with larger pharmaceutical companies, which may include upfront payments, milestone payments, and royalties based on future product sales. Additionally, eFFECTOR may engage in licensing agreements for its technology or compounds, allowing other entities to develop and market these products. The company's financial performance is heavily dependent on the successful progression of its drug candidates through clinical trials and eventual FDA approval for market release.

eFFECTOR Therapeutics Financial Statement Overview

Summary

eFFECTOR Therapeutics is experiencing severe financial difficulties across all major financial metrics, including declining revenues, increasing losses, negative equity, and insufficient cash flow generation. High leverage and reliance on external financing raise concerns about long-term viability.

Income Statement

eFFECTOR Therapeutics has faced significant revenue challenges, with revenues decreasing to zero in 2023 from $3.55 million in 2022. The company has consistently reported negative net income, with the net profit margin declining sharply due to increasing losses. The lack of revenue and high expenses have resulted in negative EBIT and EBITDA margins, indicating operational inefficiencies and financial distress.

Balance Sheet

The balance sheet reveals a concerning financial structure, with negative stockholders' equity and a high debt-to-equity ratio due to liabilities exceeding assets. The company's equity ratio is negative, pointing to potential solvency issues. The high leverage and negative equity position pose substantial risks to financial stability.

Cash Flow

Cash flow analysis shows negative free cash flow, indicating that the company is not generating sufficient cash from operations to cover its capital expenditures. Operating cash flow remains negative, and the operating cash flow to net income ratio is unfavorable. The company relies heavily on financing activities to sustain operations, reflecting a challenging cash flow situation.

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	0.00	3.55M	1.43M	42.00M	0.00
Gross Profit	-22.92M	3.50M	1.41M	20.17M	-307.00K
EBITDA	-33.73M	-32.40M	-31.90M	16.05M	-28.30M
Net Income	-35.81M	-12.93M	15.80M	14.21M	-29.74M
Balance Sheet
Total Assets	20.54M	29.08M	54.06M	16.70M	5.09M
Cash, Cash Equivalents and Short-Term Investments	18.37M	26.31M	49.70M	15.22M	3.43M
Total Debt	20.55M	20.28M	20.03M	12.96M	15.24M
Total Liabilities	26.34M	25.18M	36.77M	148.95M	18.93M
Stockholders Equity	-5.79M	3.90M	17.28M	-132.25M	-13.84M
Cash Flow
Free Cash Flow	-29.65M	-26.09M	-24.93M	13.68M	-27.60M
Operating Cash Flow	-29.55M	-25.90M	-24.89M	13.84M	-27.60M
Investing Cash Flow	14.48M	-17.86M	565.00K	-154.00K	84.00K
Financing Cash Flow	21.23M	2.77M	58.81M	-1.89M	20.24M

eFFECTOR Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.44B	-0.20	-46.00%	2.27%	22.80%	-2.27%
BDRX	45 Neutral	$467.35K	―	-89.21%	―	-100.00%	96.37%
GRI	45 Neutral	$3.60M	―	-248.95%	―	―	98.17%
SLRX	30 Underperform	$3.46M	―	-660.37%	―	―	74.27%
PCSA	29 Underperform	$11.09M	―	-212.38%	―	―	57.99%
EFTR	25 Underperform	$941.00	―	617.96%	―	―	―
QNRX	25 Underperform	$4.30M	―	-244.31%	―	―	-146.64%